ProShares UltraShort NASDAQ Biotechnology
6 hedge funds and large institutions have $547K invested in ProShares UltraShort NASDAQ Biotechnology in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
4.99% less ownership
Funds ownership: 20.12% → 15.13% (-5%)
45% less capital invested
Capital invested by funds: $992K → $547K (-$445K)
83% less call options, than puts
Call options by funds: $4K | Put options by funds: $23K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
+$342K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.11K |
| 3 |
Morgan Stanley
New York
|
+$911 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$281K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$259K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$123K |
BIS Hedge Fund Activity: Q4 2023 in Review
6 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2023, worth a combined $547K — down 45% from $992K a quarter earlier.
Fund positioning in BIS was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was IMC Chicago, opening a new position worth an estimated $342K. The largest seller was Citadel Advisors, cutting an estimated $281K.
- 6 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $547K of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2023, down 45% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2023 and 1 closed out, a net change of 0 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2023 was IMC Chicago, an estimated $342K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2023 was Citadel Advisors, an estimated $281K sold.
Based on aggregated 13F filings for Q4 2023.